Latest News of MLTX
Biotechnology Value Fund L.P. Reduces Stake in MoonLake Immunotherapeutics
By Yahoo! Finance |
1 month ago
Biotechnology Value Fund L.P. reduced its stake in MoonLake Immunotherapeutics by 2,000,000 shares, representing a 9.19% decrease, at $55.28 per share. Despite this reduction, the firm still holds 31....
Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?
By Yahoo! Finance |
1 month ago
MoonLake Immunotherapeutics (NASDAQ:MLTX) is among the top guru stocks to buy. MLTX is a biotech company developing treatments for psoriasis, focusing on a drug called sonelokimab. With strong cash re...
MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock
By Yahoo! Finance |
1 month ago
The article discusses MoonLake Immunotherapeutics and the challenges faced by foreign companies in the U.S. market. Despite geopolitical tensions, investing in foreign stocks may offer growth opportun...
-
MoonLake Immunotherapeutics (MLTX): One of Oppenheimer's Top Stock Picks For the Next 12 Months
By Yahoo! Finance | 2 months agoOppenheimer's top stock picks for the next 12 months include MoonLake Immunotherapeutics (NASDAQ: MLTX), ranking 5th. MLTX, a biotech company, is developing a treatment for various ailments. Although ...
-
We're Interested To See How MoonLake Immunotherapeutics (NASDAQ:MLTX) Uses Its Cash Hoard To Grow
By Yahoo! Finance | 3 months agoShareholders can profit from a money-losing business by investing in a promising company at a low price. MoonLake Immunotherapeutics (NASDAQ:MLTX) with a solid cash reserve of US$520m and cash burn of...